232
Participants
Start Date
July 1, 2024
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2028
Polyhexamethylene biguanide (PHMB)
PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
Topical corticosteroid
Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Topical placebo
An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
NOT_YET_RECRUITING
Columbia University, New York
NOT_YET_RECRUITING
University of Pennsylvania, Philadelphia
NOT_YET_RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
University of Florida, Gainesville
RECRUITING
University of Miami, Miami
RECRUITING
University of Iowa, Iowa City
RECRUITING
University of Illinois, Chicago, Chicago
NOT_YET_RECRUITING
University of California, Los Angeles, Los Angeles
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Federal University of São Paulo, São Paulo
RECRUITING
Aravind Eye Hospital, Coimbatore
RECRUITING
Aravind Eye Hospital, Madurai
NOT_YET_RECRUITING
Moorfields Eye Hospital, London
Johns Hopkins University
OTHER
Oregon Health and Science University
OTHER
University of Illinois at Chicago
OTHER
University of California, Los Angeles
OTHER
University of Pittsburgh
OTHER
University of Pennsylvania
OTHER
Columbia University
OTHER
University of Iowa
OTHER
University of Florida
OTHER
Aravind Eye Care System
OTHER
Moorfields Eye Hospital NHS Foundation Trust
OTHER
Federal University of São Paulo
OTHER
National Eye Institute (NEI)
NIH
University of Miami
OTHER
Jeremy Keenan, MD, MPH
OTHER